Vysnova’s Success Story: SABER II Initiative

In Southeast Asia, the SABER II program, sponsored by NAMRU-2, has been designed to enhance disease surveillance, introduce novel diagnostic methods, test effective disease control techniques, and develop local capabilities in handling diseases. This initiative addresses a range of threats, from vector-borne diseases like Malaria, Dengue, and Chikungunya, to the growing concerns of Swine Flu, Bird Flu, SARS-CoV-2, MERS-CoV, among others.

The Challenge:

The rapid emergence of highly immune-evasive SAR-Cov-2 strains highlights the importance of analyzing the components of the adaptive immune system in active-duty service members who have been exposed to COVID-19. The results of this analysis could offer vital information on the requirement for subsequent booster doses and guide the direction of future vaccine research and development.

The Solution:

Facing this challenge head-on, Vysnova, a subsidiary of Culmen International, took innovative measures. They formed a specialized team in Japan, which included two study coordinators, four lab technicians, and a data manager. Notably, the Japanese team members were spouses of US Navy service personnel, which facilitated easier access to military bases and expedited the project’s progress.

Vysnova also initiated a warehouse in Japan to accommodate study materials. By leveraging thorough market research and negotiations, they optimized the delivery process for these supplies to new research facilities. As of 23rd September 2023, their efforts bore fruit, with NAMRU-IP gathering 169 valuable samples.

The samples’ journey extended beyond Japan. Vysnova coordinated with World Courier to transport them to NMRC labs in the US for in-depth analysis, ensuring compliance with all international shipping regulations.

In collaboration with NAMRU-2, Vysnova is leading the charge against emerging infectious diseases. The SABER II program is a testament to their dedication, logistical prowess, and unwavering determination to address the challenges presented by the field of epidemiology.